Novartis Seals Deal To License High-Priced Cancer Drug
Date
10/20/2022 2:09:53 PM
(MENAFN- Swissinfo)
The impact on patients is expected to be limited given the main patent expires in July 2023. © Keystone / Patrick Straub
Swiss pharma giant Novartis has finalised a deal with the Geneva-based Medicines Patent Pool to allow generic production of its patented drug nilotinib to treat chronic myeloid leukemia.
This content was published on October 20, 2022 - 11:00 October 20, 2022 - 11:00 Jessica covers the good, the bad, and the ugly when it comes to big global companies and their impact in Switzerland and abroad. She's always looking for a Swiss connection with her native San Francisco and will happily discuss why her hometown has produced some of the greatest innovations but can't seem to solve its housing crisis.
| Español
(es)
Português
(pt)
The deal, which was formally on the sidelines of the World Cancer Congress in Geneva this week, marks the first time a pharmaceutical company is making a patented cancer medicine available through a voluntary licensing scheme.
“This is important because it's the first and helps show that voluntary licences can work for cancer drugs,” Charles Gore, the executive director of the Medicines Patent Pool (MPP), told SWI swissinfo.ch.
MENAFN20102022000210011054ID1105055176
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.